MedPath

FROVATRIPTAN

These highlights do not include all the information needed to use FROVATRIPTAN SUCCINATE TABLETS safely and effectively. See full prescribing information for FROVATRIPTAN SUCCINATE TABLETS.FROVATRIPTAN SUCCINATE tablets, for oral use Initial U.S. Approval: 2001

Approved
Approval ID

92c91060-c06e-4a8a-b586-a3fb25c33433

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 29, 2023

Manufacturers
FDA

Ingenus Pharmaceuticals, LLC

DUNS: 833250017

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

frovatriptan succinate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50742-299
Application NumberANDA213891
Product Classification
M
Marketing Category
C73584
G
Generic Name
frovatriptan succinate
Product Specifications
Route of AdministrationORAL
Effective DateNovember 29, 2023
FDA Product Classification

INGREDIENTS (9)

POLYETHYLENE GLYCOL 8000Inactive
Code: Q662QK8M3B
Classification: IACT
HYPROMELLOSE 2910 (6 MPA.S)Inactive
Code: 0WZ8WG20P6
Classification: IACT
ANHYDROUS LACTOSEInactive
Code: 3SY5LH9PMK
Classification: IACT
FROVATRIPTAN SUCCINATEActive
Quantity: 2.5 mg in 1 1
Code: D28J6W18HY
Classification: ACTIM
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
MICROCRYSTALLINE CELLULOSE 102Inactive
Code: PNR0YF693Y
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A CORNInactive
Code: AG9B65PV6B
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

FROVATRIPTAN - FDA Drug Approval Details